SynthesisAnnals of surgical oncology2025
Magnetic Sentinel Lymph Node Biopsy in Early Breast Cancer Patients: An Individual Patient Data Meta-analysis of Tracer Uptake.
Synthesis in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nanoplatforms for Sentinel and Tumor-Draining Lymph Node Mapping: From Visualization to Pathway-Informed Staging.Advanced healthcare materials · 2026Review
- Magnetic particle imaging tracers for human applications: preclinical in vivo evaluation of Magtrace, Resotran, and FerroTrace.Npj imaging · 2026Article
- Sentinel lymph node detection in early-stage breast cancer - Are technetium-99m-nanocolloid and superparamagnetic iron oxide diagnostically equivalent procedures? A propensity score matched real world data analysis.Breast (Edinburgh, Scotland) · 2026Article
- Dose Comparison (1 mL versus 2 mL) of Superparamagnetic Tracer for Sentinel Node Biopsy in Early Breast Cancer: Real-World Analysis from 456 Patients.Breast care (Basel, Switzerland) · 2026Article
- Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study.The British journal of surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuperparamagnetic iron oxide nanoparticles (SPIO) are emerging as a viable alternative to technetium and blue dye. Our study was designed to evaluate the correlation between SPIO dose, injection site, and timing with sentinel lymph node (SLN) detection and iron content in retrieved SLNs.
methodsThis study combined individual patient data from three Dutch and five Swedish studies. Associations between SLN detection and dose, site, and timeframe of SPIO injection were examined. The iron content for each retrieved SLNs with or without metastases were calculated according to a predefined look up table based on probe counts and sensitivity setting. Analyses were conducted by using multivariable logistic and linear regression models using generalized estimating equation.
resultsA total of 908 patients were included. The detection between the magnetic technique (96.6%) and the radioactive technique was comparable (96.6% vs. 96.8%, p = 0.75). The 1.0-mL SPIO dose was associated with the highest, and <0.5 mL of SPIO was associated with the lowest patient-based detection (100.0 and 96.6% respectively). An intratumoural injection was found to be less favourable compared with peritumoural and subareolar, whereas injection >168 hours before surgery demonstrated the highest patient-based detection.
conclusionsThe noninferiority of SPIO compared with technetium99m ± BD has been proven by several studies. A dose of 1 mL, around the areola, with a longer exposure time, appears to increase the SPIO uptake in the nodes and SLN detection. Metastatic burden in SLNs did not significantly impact the uptake of SPIO.
Indexed as
Identifiers
39690385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.